Bionxt Solutions Inc. Stock
€0.13
Your prediction
Financial data and news for Bionxt Solutions
sharewise wants to provide you with the best news and tools for Bionxt Solutions, so we directly link to the best financial data sources.
Financials
News
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
VANCOUVER, BC / ACCESSWIRE / August 15, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a non-binding letter
BioNxt Signs Statement of Work with International Contract Research, Development, And Manufacturing Organization for Cladribine ODF Development
VANCOUVER, BC / ACCESSWIRE / July 17, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a statement of work
BioNxt Signs Master Services Agreement with International Contract Research, Development, and Manufacturing Organization
VANCOUVER, BC / ACCESSWIRE / July 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that it has signed a master services
BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps
VANCOUVER, BC / ACCESSWIRE / March 18, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that based on the recent success of its
BioNxt Reports Successful Results From ODF Cladribine PK Study
VANCOUVER, BC / ACCESSWIRE / March 13, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic
BioNxt Reports Completion of ODF Cladribine PK Study
VANCOUVER, BC / ACCESSWIRE / March 4, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report that the comparative pharmacokinetic